|Videos|April 1, 2022

Impact of Long-Acting HIV Prevention Drugs

A panel of experts discuss the role of PrEP in HIV prevention with a focus on current and newly approved options.

Episodes in this series


Related to this article

Could Linvoseltamab Change When We Treat High-Risk Smoldering Myeloma?
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.